Friday, December 20, 2024 8:44:10 PM
Recent RXRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 11:02:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 11:02:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 11:02:30 PM
- Recursion to Present at 43rd Annual JP Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2025 01:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/26/2024 09:24:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2024 09:16:57 PM
- Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules • GlobeNewswire Inc. • 12/20/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2024 11:49:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/17/2024 10:06:27 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 12/17/2024 10:05:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/11/2024 09:48:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/10/2024 09:56:42 PM
- Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability • GlobeNewswire Inc. • 12/09/2024 11:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 10:46:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/05/2024 03:29:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/04/2024 03:32:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2024 09:40:55 PM
- Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma • GlobeNewswire Inc. • 12/03/2024 01:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/03/2024 12:02:36 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/27/2024 09:09:08 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/26/2024 09:48:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2024 11:25:51 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2024 11:25:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/21/2024 09:24:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2024 12:14:18 PM
CGRA Signs Binding Term Sheet to Merge With American Infrastructure Corporation, a Subsidiary of Nasdaq-listed American Resources Corporation (Nasdaq: AREC) • CGRA • Jan 6, 2025 10:31 AM
UAV Corp (UMAV) Working on Securing $1.5 Billion in Contracts and Announces Groundbreaking Partnership with Atlantic Industrial Group • UMAV • Jan 6, 2025 9:26 AM
Basanite, Inc. to Open New Production and Distribution Facility in Northeast Ohio • BASA • Jan 2, 2025 8:28 AM
The Crypto Company Highlights Blockchain Training Alliance's Successes and Momentum for 2025 • CRCW • Dec 26, 2024 8:58 AM
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM